ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Organon and Co

Organon and Co (OGN)

14.58
0.14
(0.97%)
Closed December 21 4:00PM
14.66
0.08
(0.55%)
After Hours: 7:26PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
14.66
Bid
-
Ask
-
Volume
31,578,252
14.41 Day's Range 14.915
13.14 52 Week Range 23.10
Market Cap
Previous Close
14.44
Open
14.5347
Last Trade
3
@
14.66
Last Trade Time
Financial Volume
$ 463,368,407
VWAP
14.6737
Average Volume (3m)
2,733,601
Shares Outstanding
257,538,875
Dividend Yield
7.64%
PE Ratio
3.67
Earnings Per Share (EPS)
3.97
Revenue
6.26B
Net Profit
1.02B

About Organon and Co

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada. Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Organon and Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker OGN. The last closing price for Organon was $14.44. Over the last year, Organon shares have traded in a share price range of $ 13.14 to $ 23.10.

Organon currently has 257,538,875 shares outstanding. The market capitalization of Organon is $3.72 billion. Organon has a price to earnings ratio (PE ratio) of 3.67.

Organon (OGN) Options Flow Summary

Overall Flow

Bearish

Net Premium

-108k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

OGN Latest News

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P...

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

EFFICACY: In the pivotal studies, ADORING 1 and ADORING 2, up to 46% of patients on VTAMA cream achieved vIGA-AD™ treatment success at Week 8 versus 18% of patients on vehicle. POWERFUL SKIN...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by...

米国FDAが、PROLIA/XGEVA(デノスマブ)のバイオシミラー候補HLX14の生物学的製剤承認申請(BLA)を受理

(ビジネスワイヤ) -- シャンハイ・ヘンリウス・バイオテック(2696.HK)とオルガノン(NYSE:OGN)は、米国食品医薬品局(FDA)がPROLIA/XGEVA(デノスマブ)の治験中のバイオシミラーであるHLX14の生物学的...

美國FDA接受PROLIA/XGEVA(地諾單抗)生物學名藥候選藥物HLX14的生物製品授權申請(BLA)

(美國商業資訊)-- Shanghai Henlius Biotech, Inc. (2696.HK)和Organon (NYSE: OGN)宣布,美國食品藥物管理局(FDA)已接受PROLIA/XGEVA(地諾單抗)的試驗性生物學名藥HLX14的生物製品授權申請(BLA)。 本新聞稿包...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.49-3.2343234323415.1515.4114.385400672714.76341137CS
4-0.365-2.4292845257915.02516.2914.385307250615.26503163CS
12-4.73-24.394017534819.3919.4114.385273360116.37516259CS
26-5.56-27.497527200820.2223.114.385218384618.14204726CS
521.128.271787296913.5423.113.14234329717.87530933CS
156-15.34-51.13333333333039.47510.835238075421.84105178CS
260-19.54-57.13450292434.239.47510.835247460523.73025449CS

OGN - Frequently Asked Questions (FAQ)

What is the current Organon share price?
The current share price of Organon is $ 14.66
How many Organon shares are in issue?
Organon has 257,538,875 shares in issue
What is the market cap of Organon?
The market capitalisation of Organon is USD 3.72B
What is the 1 year trading range for Organon share price?
Organon has traded in the range of $ 13.14 to $ 23.10 during the past year
What is the PE ratio of Organon?
The price to earnings ratio of Organon is 3.67
What is the cash to sales ratio of Organon?
The cash to sales ratio of Organon is 0.6
What is the reporting currency for Organon?
Organon reports financial results in USD
What is the latest annual turnover for Organon?
The latest annual turnover of Organon is USD 6.26B
What is the latest annual profit for Organon?
The latest annual profit of Organon is USD 1.02B
What is the registered address of Organon?
The registered address for Organon is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Organon website address?
The website address for Organon is www.organon.com
Which industry sector does Organon operate in?
Organon operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VNCEVince Holding Corp
$ 4.70
(69.06%)
1.06M
SRFMSurf Air Mobility Inc
$ 3.33
(23.79%)
376.77k
BBBlackBerry Limited
$ 3.685
(23.66%)
40.8M
ALURAllurion Technologies Inc
$ 0.3439
(22.87%)
744.34k
CLWClearWater Paper Corporation
$ 30.26
(22.46%)
3.5M
IIPRInnovative Industrial Properties Inc
$ 73.50
(-22.91%)
3.15M
KUKEKuke Music Holding Limited
$ 0.31
(-20.51%)
61.21k
NVONovo Nordisk
$ 85.00
(-17.83%)
53.78M
CANGCango Inc
$ 5.08
(-11.81%)
2.27M
BNEDBarnes and Noble Education Inc
$ 9.965
(-10.31%)
1.52M
QBTSD Wave Quantum Inc
$ 6.638
(4.21%)
124.42M
PFEPfizer Inc
$ 26.36
(2.29%)
116.33M
APOApollo Global Management Inc
$ 171.03
(0.83%)
94.52M
TAT&T Inc
$ 22.75
(0.80%)
93.94M
FFord Motor Company
$ 9.885
(1.49%)
87.66M

OGN Discussion

View Posts
Monksdream Monksdream 11 months ago
OGN not so hot from a chart standpoint
👍️0
LordDarley LordDarley 4 years ago
Looks good.
There is also a very nice analysis on seeking Alpha. Shows pros and cons, and is professional quality IMHO. Much more detail than the Barron's article.
👍️0
DewDiligence DewDiligence 4 years ago
Barron’s bullish on OGN:

https://www.barrons.com/articles/jobs-report-fed-interest-rates-inflation-51622846230 Organon (OGN), which Merck (MRK) jettisoned this past week, could be another winner. This is a classic spinoff situation. Organon is a group of noncore Merck businesses—off-patent drugs sold mainly overseas, biosimilars, and a women’s health business—that may fare better as an independent company.
“You easily can see how this business could have been lost inside of Merck and been undermanaged relative to the rest of the portfolio,” says James Hounsell, a senior research analyst at Smead Capital Management, a Merck shareholder. “That’s when the magic happens with spinoffs.”

The shares trade around $34, giving the company a market value of $8.6 billion, plus about $9 billion of net debt. Merck shareholders received one Organon share for every 10 of Merck. Organon trades for just six times 2020 profits of $5.90 a share. Similar earnings are expected this year.

Organon isn’t as cheap when valued against projected 2021 earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.3 billion, based on its enterprise value of equity value plus net debt. Then, it trades around eight times, in line with mature drug companies.

At a May investor day, Merck projected $6.1 billion to $6.4 billion of 2021 revenue for Organon and annual sales increases in the low- to mid-single digits. The dividend hasn’t been set yet, but based on Organon’s financial guidance, it could be about 3%.

Major drivers for the company are expected to be an implantable women’s contraceptive called Nexplanon and biosimilars, which are generic versions of bioengineered drugs.

“This is a stable, predictable business with low- to mid-single digit growth organically,” Organon CEO Kevin Ali tells Barron’s. He is bullish on the growth outlook for the women’s health business, now about 25% of revenue, plus the opportunity for potential acquisitions.

Given its low price/earnings ratio, Organon has good appreciation potential if it can deliver on its financial goals.
👍️0
DewDiligence DewDiligence 4 years ago
OGN spin-off from MRK begins trading today:

https://www.businesswire.com/news/home/20210602006079/en
👍️0

Your Recent History

Delayed Upgrade Clock